Literature DB >> 19148882

Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn.

Susan E Andrade1, Heather McPhillips, David Loren, Marsha A Raebel, Kimberly Lane, James Livingston, Denise M Boudreau, David H Smith, Robert L Davis, Mary E Willy, Richard Platt.   

Abstract

PURPOSE: To determine the prevalence of persistent pulmonary hypertension of the newborn (PPHN) among infants whose mothers were exposed to antidepressants in the third trimester of pregnancy compared to the prevalence among infants whose mothers were not exposed to antidepressants in the third trimester.
METHODS: A retrospective study was conducted using the automated databases of four health plans participating in the HMO Research Network Center for Education and Research on Therapeutics. Women who delivered an infant in a hospital from 1 January 1996 through 31 December 2000 were identified. The administrative databases were used to identify full-term infants whose mothers received an antidepressant during the third trimester of pregnancy and unexposed infants whose mothers did not receive an antidepressant during the third trimester. Hospitalization data were used to identify diagnoses or procedure codes potentially indicative of PPHN.
RESULTS: Among 1104 infants exposed to antidepressants in the third trimester and a matched sample of 1104 unexposed infants, five infants were classified by the expert reviewers as having PPHN. Among those infants whose mothers were exposed to selective serotonin reuptake inhibitors (SSRIs) in the third trimester, the prevalence of PPHN was 2.14 per 1000 (95% confidence interval (CI) 0.26, 7.74), while the prevalence among infants whose mothers were not exposed was 2.72 per 1000 (95%CI 0.56, 7.93).
CONCLUSIONS: We did not find an association between SSRI use in late pregnancy and PPHN. Limitations of the present study, including the small number of confirmed cases, suggest further research in this area may be warranted. (c) 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19148882     DOI: 10.1002/pds.1710

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  39 in total

Review 1.  Investigating outcomes following the use of selective serotonin reuptake inhibitors for treating depression in pregnancy: a focus on methodological issues.

Authors:  Luke E Grzeskowiak; Andrew L Gilbert; Janna L Morrison
Journal:  Drug Saf       Date:  2011-11-01       Impact factor: 5.606

2.  Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn.

Authors:  Krista F Huybrechts; Brian T Bateman; Kristin Palmsten; Rishi J Desai; Elisabetta Patorno; Chandrasekar Gopalakrishnan; Raisa Levin; Helen Mogun; Sonia Hernandez-Diaz
Journal:  JAMA       Date:  2015-06-02       Impact factor: 56.272

Review 3.  Antidepressant use in pregnancy: a critical review focused on risks and controversies.

Authors:  N Byatt; K M Deligiannidis; M P Freeman
Journal:  Acta Psychiatr Scand       Date:  2012-12-14       Impact factor: 6.392

4.  SSRI and SNRI use during pregnancy and the risk of persistent pulmonary hypertension of the newborn.

Authors:  Anick Bérard; Odile Sheehy; Jin-Ping Zhao; Évelyne Vinet; Sasha Bernatsky; Michal Abrahamowicz
Journal:  Br J Clin Pharmacol       Date:  2017-01-18       Impact factor: 4.335

5.  Update on PPHN: mechanisms and treatment.

Authors:  Jayasree Nair; Satyan Lakshminrusimha
Journal:  Semin Perinatol       Date:  2014-03       Impact factor: 3.300

6.  Continuing medical education: SSRIs and pregnancy.

Authors:  Chittaranjan Andrade
Journal:  Indian J Psychiatry       Date:  2010-01       Impact factor: 1.759

Review 7.  Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy: A Review of Current Evidence.

Authors:  Sura Alwan; Jan M Friedman; Christina Chambers
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

8.  Methods of linking mothers and infants using health plan data for studies of pregnancy outcomes.

Authors:  Karin E Johnson; Sarah J Beaton; Susan E Andrade; T Craig Cheetham; Pamela E Scott; Tarek A Hammad; Inna Dashevsky; William O Cooper; Robert L Davis; Pamala A Pawloski; Marsha A Raebel; David H Smith; Sengwee Toh; De-Kun Li; Katherine Haffenreffer; Sascha Dublin
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-04-18       Impact factor: 2.890

9.  Validation of an algorithm to estimate gestational age in electronic health plan databases.

Authors:  Qian Li; Susan E Andrade; William O Cooper; Robert L Davis; Sascha Dublin; Tarek A Hammad; Pamala A Pawloski; Simone P Pinheiro; Marsha A Raebel; Pamela E Scott; David H Smith; Inna Dashevsky; Katherine Haffenreffer; Karin E Johnson; Sengwee Toh
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-01-21       Impact factor: 2.890

10.  Depression during pregnancy: views on antidepressant use and information sources of general practitioners and pharmacists.

Authors:  Tessa Ververs; Liset van Dijk; Somaye Yousofi; Fred Schobben; Gerard H A Visser
Journal:  BMC Health Serv Res       Date:  2009-07-17       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.